Honored to join the podcast “In the Thick of It” by the Hypertrophic Cardiomyopathy Society to discuss our recent work on beta blockers and calcium channel blockers in non-obstructive HCM.
#HCM #hcmsociety
Beta Blockers:New Evidence in Non-Obstructive HCM Care. The latest episode of “In the Thick of It,”an HCMS podcast sponsored by Cytokinetics.Essential for those moving beyond expert opinion to evidence-based, personalized care bit.ly/4f0lGJp
#hcmpodcast #HCM #hcmsociety
57
Appreciate the comments - glad to see our study sparking discussion 🫀
I realize beta-blockers have not been shown beneficial in non-obstructive HCM, but, they are commonly prescribed here and in HFpEF. I like this study. It shows clearly that BB worsen exercise capacity.
BB have very selective indications. I am not sure why they are popular
71
Our RCT comparing bisoprolol and verapamil in non-obstructive HCM is now published in #JACC ✨
- Bisoprolol: ↓ pVO₂, ↑ NT-proBNP & ↓ KCCQ
- Verapamil: No change in pVO₂ & KCCQ, ↓ NT-proBNP
🔗authors.elsevier.com/a/1miXb…
#HCM #Clinicaltrial
50
In obstructive #HCM, #pVO2, #NYHA, and #KCCQ don’t always align!
Weak correlations and frequent patient-level discordance raise considerations for optimal metric selection in clinical practice and clinical trial design.
🔗kwnsfk27.r.eu-west-1.awstrac…
Louise Bjerregaard retweeted
Thank you @DCAcademyDK for an amazing #dcasummermeeting23 ☀️
We already look forward to next year’s meeting 🫀





